Related Experiment Video
Updated: Dec 5, 2025
08:30
Neonatal Murine Cochlear Explant Technique as an In Vitro Screening Tool in Hearing Research
Published on: June 8, 2017
18.4K
Potential Benefit of Selective CMV Testing after Failed Newborn Hearing Screening
Peter Kummer1, Steven C Marcrum2
1Section Phoniatrics and Pediatric Audiology, Department of Otolaryngology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.
International Journal of Neonatal Screening
|October 19, 2020
Summary
Selective congenital cytomegalovirus (cCMV) testing can significantly improve identification of cCMV-related sensorineural hearing loss (SNHL). Antiviral therapies show promise for newborns identified through this approach.
Area of Science:
- Virology
- Audiology
- Neonatal Medicine
Background:
- Congenital cytomegalovirus (cCMV) is a leading cause of sensorineural hearing loss (SNHL) in newborns.
- Recent guidelines emphasize cCMV's impact on SNHL and recommend antiviral therapies.
- Current clinical identification of cCMV-related SNHL is low, estimated at less than 10%.
Purpose of the Study:
- To estimate the proportion of cCMV-related SNHL cases identifiable via selective cCMV testing after failed newborn hearing screening.
- To assess the potential benefit of antiviral therapies for affected newborns.
Main Methods:
- Literature review to analyze cCMV-related SNHL identification rates.
- Evaluation of expert group recommendations on antiviral treatment for cCMV.
Main Results:
- Currently, less than 10% of cCMV-related SNHL is clinically identified.
- Selective cCMV testing following failed newborn hearing screening can substantially increase identification rates.
- Antiviral therapy is recommended for moderate-to-severe cCMV disease, with potential benefits for newborns with isolated SNHL or mild symptoms.
Conclusions:
- Implementing selective cCMV testing is crucial for improving the diagnosis of cCMV-related SNHL.
- A significant number of newborns with cCMV may benefit from emerging antiviral treatments.
- Early identification and treatment are key to managing the burden of cCMV-induced hearing loss.
